<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00707772</url>
  </required_header>
  <id_info>
    <org_study_id>BRCGL-07-03</org_study_id>
    <secondary_id>BRCGL-07-03</secondary_id>
    <nct_id>NCT00707772</nct_id>
  </id_info>
  <brief_title>Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection</brief_title>
  <official_title>A Study on PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) in Iranian Hemophilic Patients With Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baqiyatallah Medical Sciences University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tehran Hepatitis Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guilan Research Center for Gastroenterology and Liver Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tabriz Research Center for Gastroenterology and Liver Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Iran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baqiyatallah Medical Sciences University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemophilic patients are a known high risk groups for acquiring the hepatitis C. The
      surveillance data from Ministry Of Health in IR.Iran had shown that 60% of them are infected
      with HCV infection. We are trying the PEGASYS plus Ribavirin in Hemophilic patients with HCV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators enroll 400 patients into the study. The patients receive PEGASYS
      (Peginterferon alpha-2a(40 KD)) 180 microgram per week plus COPEGUS (Ribavirin) 800 microgram
      for Genotype 2 and 3 and 1000 milligram for weight less than 75 kg and 1200 milligram for
      more than 75 kg. The duration of protocol is depends on genotypes of virus. In genotype 1 and
      4, for 48 week and in genotypes 2 and 3 , for 24 weeks. The patients are visited every 4
      weeks with biochemistry lab tests. The patients are checked with quantitative HCV RNA on the
      third months after initiation of the treatment to assess early virologic response and at the
      end of the study for complete response rate and on the six month after treatment completion
      for sustained response rate. The patients with undetectable HCV RNA are considered as
      responders. We have omitted the liver biopsy in the patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Virologic Response</measure>
    <time_frame>After 12 weeks of Treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>End of Treatment Response</measure>
    <time_frame>24 weeks for : Genotype 2 &amp; 3; 48 Weeks for other genotype</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained Virologic Response</measure>
    <time_frame>24 weeks after Treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapid Virologic Response</measure>
    <time_frame>One month after Treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of drugs for whole therapy period</measure>
    <time_frame>During Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical response (ALT)</measure>
    <time_frame>End of Treatment AND 24 weeks after Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameters</measure>
    <time_frame>During Treatment AND End of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Hemophilia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Genotype 2 or 3 in Hemophilic Patients with HCV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Other Genotypes (except 2 or 3) in Hemophilic Patients with HCV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)</intervention_name>
    <description>PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: 800 milligram per day (PO)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Peginterferon Alfa-2a (40KD) Plus COPEGUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)</intervention_name>
    <description>PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: [=&lt;75 kg: 1000 mg; &gt;75 kg: 1200 mg per day (PO)]</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Peginterferon Alfa-2a (40KD) plus COPEGUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV RNA positive

          -  Age older than 12 years

        Exclusion Criteria:

          -  Ongoing pregnancy or breast feeding

          -  Hx of HCC

          -  Hx of alcoholic liver disease

          -  Hx of bleeding from esophageal varices

          -  Hx of hemochromatosis

          -  Hx of autoimmune hepatitis

          -  Hx of Suicidal attempt

          -  Hx of cerebrovascular dis

          -  Hx of severe retinopathy

          -  Hx of severe psoriasis

          -  Hx of scleroderma

          -  Hx of metabolic liver disease

          -  Hx of SLE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Seyed-Moayed Alavian, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seyyed Mohammad Miri, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maryam Keshvari, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iranian blood Transfusion Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bita Behnava, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Hossein Somi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Center for Gastroenterology and Hepatology, Tabriz University of Medical Sciences, Tabriz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fariborz Mansour-Ghanaei, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology and Liver Diseases, Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pegah Karimi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bashir HajiBeigi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iranian Blood Transfusion Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</name>
      <address>
        <city>Tehran</city>
        <zip>14155-3651</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Iafolla M. [Pegasys: FDA approved Pegasys (peginterferon alfa-2a) for the treatment of hepatitis C]. Sidahora. 2002;(4):8-10. Spanish.</citation>
    <PMID>12703472</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2008</study_first_submitted>
  <study_first_submitted_qc>June 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2008</study_first_posted>
  <last_update_submitted>September 16, 2009</last_update_submitted>
  <last_update_submitted_qc>September 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Professor Seyed-Moayed Alavian</name_title>
    <organization>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</organization>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Hemophilia</keyword>
  <keyword>Pegasys</keyword>
  <keyword>Ribavirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

